Optimal sequence of hormonotherapy in advanced breast cancer

Current Opinion in Oncology

Volumn 18, Issue 6, 2006, Pages 572-577

  Bertelli, Gianfilippo ^a   Paridaens, Robert ^b  

^a SINGLETON HOSPITAL   (United Kingdom)

^b UNIVERSITY HOSPITALS LEUVEN   (Belgium)

Author keywords

Anastrozole; Exemestane; Fulvestrant; Letrozole; Tamoxifen

Indexed keywords

ANASTROZOLE; AROMATASE INHIBITOR; ESTROGEN RECEPTOR; EXEMESTANE; FORMESTANE; FULVESTRANT; GESTAGEN; HORMONE RECEPTOR; LETROZOLE; MEGESTROL ACETATE; TAMOXIFEN; VOROZOLE;

ADVANCED CANCER; BREAST CANCER; CANCER CONTROL; CANCER HORMONE THERAPY; CANCER PATIENT; CLINICAL TRIAL; DRUG HYPERSENSITIVITY; DRUG TOLERABILITY; DYSPNEA; FEMALE; HOT FLUSH; HUMAN; PERIPHERAL EDEMA; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; POSTMENOPAUSE; PRIORITY JOURNAL; QUALITY OF LIFE; RECEPTOR DOWN REGULATION; REVIEW; SIDE EFFECT; TREATMENT OUTCOME; WEIGHT GAIN;

ANTINEOPLASTIC AGENTS; AROMATASE INHIBITORS; BREAST NEOPLASMS; FEMALE; HUMANS; NEOPLASMS, HORMONE-DEPENDENT;

EID: 33748914070     PISSN: 10408746     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.cco.0000245313.97638.1d     Document Type: Review

References (39)

1. Ingle JN. Sequencing of endocrine therapy in postmenopausal women with advanced breast cancer. Clin Cancer Res 2004; 10 (1 Pt 2):362S-367S.
2. Bertelli G. Sequencing of aromatase inhibitors. Br J Cancer 2005; 93 (Suppl 1):S6-S9.
3. Dodwell D, Wardley A, Johnston S. Postmenopausal advanced breast cancer: options for therapy after tamoxifen and aromatase inhibitors. Breast 2006 Feb 24; [Epub ahead of print].
4. Howell A, Cuzick J, Baum M, et al. Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer. Lancet 2005; 365:60-62.
5. Thurlimann B, Keshaviah A, Coates AS, et al. A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer. N Engl J Med 2005; 353:2747-2757.
6. Coombes RC, Hall E, Gibson LJ, et al. A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer. N Engl J Med 2004; 350:1081-1092.
7. Goss PE, Ingle JN, Martino S, et al. Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: updated findings from NCIC CTG MA.17. J Natl Cancer Inst 2005; 97:1262-1271.
8. Nabholtz JM, Bonneterre J, Buzdar A, et al. Anastrozole (Arimidex) versus tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: survival analysis and updated safety results. Eur J Cancer 2003; 39:1684-1689.
9. Mouridsen H, Gershanovich M, Sun Y, et al. Phase III study of letrozole versus tamoxifen as first-line therapy of advanced breast cancer in postmenopausal women: analysis of survival and update of efficacy from the International Letrozole Breast Cancer Group. J Clin Oncol 2003; 21:2101-2109.
10. Paridaens R, Therasse P, Dirix L, et al. First line hormonal treatment (HT) for metastatic breast cancer (MBC) with exemestane (E) or tamoxifen (T) in postmenopausal patients (pts): a randomized phase III trial of the EORTC breast group [abstract]. Proc Am Soc Clin Oncol 2004; 23:6.
11. Freedman OC, Verma S, Clemons MJ. Using aromatase inhibitors in the neoadjuvant setting: evolution or revolution? Cancer Treat Rev 2005; 31:1-17.
12. Abrial C, Mouret-Reynier MA, Cure H, et al. Neoadjuvant endocrine therapy in breast cancer. Breast 2006; 15:9-19.
13. Jonat W, Howell A, Blomqvist C, et al. A randomised trial comparing two doses of the new selective aromatase inhibitor anastrozole (Arimidex) with megestrol acetate in postmenopausal patients with advanced breast cancer. Eur J Cancer 1996; 32:404-412.
14. Buzdar AU, Jones SE, Vogel CL, et al. A phase III trial comparing anastrozole (1 and 10 milligrams), a potent and selective aromatase inhibitor, with megestrol acetate in postmenopausal women with advanced breast carcinoma. Arimidex Study Group. Cancer 1997; 79:730-739.
15. Dombernowsky P, Smith I, Falkson G, et al. Letrozole, a new oral aromatase inhibitor for advanced breast cancer: double-blind randomized trial showing a dose effect and improved efficacy and tolerability compared with megestrol acetate. J Clin Oncol 1998; 16:453-461.
16. Kaufmann M, Bajetta E, Dirix LY, et al. Exemestane is superior to megestrol acetate after tamoxifen failure in postmenopausal women with advanced breast cancer: results of a phase III randomized double-blind trial. The Exemestane Study Group. J Clin Oncol 2000; 18:1399-1411.
17. Buzdar A, Douma J, Davidson N, et al. Phase III, multicenter, double-blind, randomized study of letrozole, an aromatase inhibitor, for advanced breast cancer versus megestrol acetate. J Clin Oncol 2001; 19:3357-3366.
18. Rose C, VtorayaO, Pluzanska A, et al. An open randomised trial of second-line endocrine therapy in advanced breast cancer: comparison of the aromatase inhibitors letrozole and anastrozole. Eur J Cancer 2003; 39:2318-2327.
19. Bundred N. Preclinical and clinical experience with fulvestrant (Faslodex) in postmenopausal women with hormone receptor-positive advanced breast cancer. Cancer Invest 2005; 23:173-181. A review on the estrogen receptor downregulator fulvestrant as first-line or secondline endocrine therapy in advanced breast cancer.
20. Robertson JF, Come SE, Jones SE, et al. Endocrine treatment options for advanced breast cancer: the role of fulvestrant. Eur J Cancer 2005; 41:346-356. The article examines the key efficacy and tolerability data for fulvestrant and its potential role within the sequencing of endocrine therapy in advanced breast cancer.
21. Howell A, Robertson JF, Quaresma Albano J, et al. Fulvestrant, formerly ICI 182, 780, is as effective as anastrozole in postmenopausal women with advanced breast cancer progressing after prior endocrine treatment. J Clin Oncol 2002; 20:3396-3403.
22. Osborne CK, Pippen J, Jones SE, et al. Double-blind, randomized trial comparing the efficacy and tolerability of fulvestrant versus anastrozole in postmenopausal women with advanced breast cancer progressing on prior endocrine therapy: results of a North American trial. J Clin Oncol 2002; 20:3386-3395.
23. Howell A, Pippen J, Elledge RM, et al. Fulvestrant versus anastrozole for the treatment of advanced breast carcinoma: a prospectively planned combined survival analysis of two multicenter trials. Cancer 2005; 104:236-239. Data were combined from the above two trials (Howell et al., J Clin Oncol 2002, 20:3396 and Osborne et al., J Clin Oncol 2002, 20:3386) comparing intramuscular fulvestrant 250mg monthly (n = 428) with anastrozole 1mg daily (n = 423) as second-line endocrine therapy in advanced breast cancer. The trials were designed to demonstrate superiority of fulvestrant compared with anastrozole. The results of the combined analysis suggest noninferiority of fulvestrant in terms of time to progression and a lower incidence of arthralgias.
24. Dodwell D, Vergote I. A comparison of fulvestrant and the third-generation aromatase inhibitors in the second-line treatment of postmenopausal women with advanced breast cancer. Cancer Treat Rev 2005; 31:274-282. A literature-based comparison of the performance of fulvestrant and other agents (anastrozole, letrozole, exemestane) as second-line endocrine therapy in advanced breast cancer.
25. Thurlimann B, Paridaens R, Serin D, et al. Third-line hormonal treatment with exemestane in postmenopausal patients with advanced breast cancer progressing on aminoglutethimide: a phase II multicentre multinational study. Eur J Cancer 1997; 33:1767-1773.
26. Lønning PE, Bajetta E, Murray R, et al. Activity of exemestane in metastatic breast cancer after failure of nonsteroidal aromatase inhibitors: a phase II trial. J Clin Oncol 2000; 18:2234-2244.
27. Iaffaioli RV, Formato R, Tortoriello A, et al. Phase II study of sequential hormonal therapy with anastrozole/exemestane in advanced and metastatic breast cancer. Br J Cancer 2005; 92:1621-1625. In this phase II study, patients with advanced breast cancer received anastrozole first and were switched to exemestane at the time of progression.
28. Steele N, Zekri J, Coleman R, et al. Exemestane in metastatic breast cancer: effective therapy after third-generation nonsteroidal aromatase inhibitor failure. Breast 2005 Oct 14; [Epub ahead of print]. Retrospective study of exemestane after treatment with nonsteroidal aromatase inhibitors in advanced breast cancer.
29. Johnston SR, Martin LA, Dowsett M. Life following aromatase inhibitors: where now for endocrine sequencing? Breast Cancer Res Treat 2005; 93(Suppl 1):S19-S25.
30. Ingle JN, Suman VJ, Rowland KM, et al. Fulvestrant in women with advanced breast cancer after progression on prior aromatase inhibitor therapy: North Central Cancer Treatment Group Trial N0032. J Clin Oncol 2006; 24:1052-1056. In this study, fulvestrant showed antitumor activity and good tolerability after failure of aromatase inhibitors in advanced breast cancer. With the increased use of aromatase inhibitors in the adjuvant setting, these results suggest that fulvestrant may be an option at the time of first relapse.
31. Thurlimann B, Robertson JF, Nabholtz JM, et al., Arimidex Study Group. Efficacy of tamoxifen following anastrozole ('Arimidex') compared with anastrozole following tamoxifen as first-line treatment for advanced breast cancer in postmenopausal women. Eur J Cancer 2003; 39:2310-2317.
32. Bertelli G, Garrone O, Merlano M, et al. Sequential treatment with exemestane and nonsteroidal aromatase inhibitors in advanced breast cancer. Oncology 2005; 69:471-477. Mirroring previous studies on the sequential use of steroidal and nonsteroidal aromatase inhibitors in advanced breast cancer, patients in this trial received exemestane first and letrozole or anastrozole at the time of progression.
33. Robertson JF, Howell A, Gorbunova VA, et al. Sensitivity to further endocrine therapy is retained following progression on first-line fulvestrant. Breast Cancer Res Treat 2005; 92:169-174. If fulvestrant is used as first-line therapy instead of tamoxifen, second-line endocrine therapies can still elicit response or stabilization in advanced breast cancer.
34. Howell A, Robertson JF, Abram P, et al. Comparison of fulvestrant versus tamoxifen for the treatment of advanced breast cancer in postmenopausal women previously untreated with endocrine therapy: a multinational, double-blind, randomized trial. J Clin Oncol 2004; 22:1605-1613.
35. Steger GG, Bartsch R, Wenzel C, et al. Fulvestrant ('Faslodex') in pretreated patients with advanced breast cancer: a single-centre experience. Eur J Cancer 2005; 41:2655-2661. Fulvestrant was used at various points of the endocrine therapy sequence in this single-centre report.
36. Carlini P, Bria E, Giannarelli D, et al. New aromatase inhibitors as second-line endocrine therapy in postmenopausal patients with metastatic breast carcinoma: a pooled analysis of the randomized trials. Cancer 2005; 104:1335-1342. Interesting meta-analysis of published trials comparing aromatase inhibitors with megestrol acetate as second-line therapy in advanced breast cancer.
37. Fossati R, Confalonieri C, Torri V, et al. Cytotoxic and hormonal treatment for metastatic breast cancer: a systematic review of published randomized trials involving 31,510 women. J Clin Oncol 1998; 16:3439-3460.
38. Bertelli G, Garrone O, Bertolotti L, et al. Maintenance hormone therapy with letrozole after first-line chemotherapy for advanced breast cancer. Oncology 2005; 68:364-370. The study addresses the sequential use of chemotherapy and chemohormonal therapy, using letrozole as a maintenance treatment following first-line chemotherapy in advanced breast cancer.
39. Johnston SR, Martin LA, Head J, et al. Aromatase inhibitors: combinations with fulvestrant or signal transduction inhibitors as a strategy to overcome endocrine resistance. J Steroid Biochem Mol Biol 2005; 95:173-181. Review of preclinical data on endocrine resistance and the implications for clinical trials.